Trial Profile
Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Lymphangioleiomyomatosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms MIDAS
- 11 Jan 2022 Planned End Date changed from 1 Aug 2021 to 1 Aug 2024.
- 11 Jan 2022 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2023.
- 28 Oct 2020 Planned End Date changed from 1 Apr 2020 to 1 Aug 2021.